IRONWOOD RAISES 2026 GUIDANCE AMID STRONG LINZESS SALES
Ironwood Pharmaceuticals raised total revenue and adjusted EBITDA guidance for 2026, citing strong LINZESS performance, while also repaying convertible notes and initiating a confirmatory Phase 3 trial for apraglutide.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day